Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

Sugano, Teppei; Seike, Masahiro; Funasaka, Yoko; Yoshida, Masahide; Takayama, Ryoko; Okamura, Ken; Nakanishi, Asuka; Tanaka, Toru; Takeuchi, Susumu; Noro, Rintaro; Minegishi, Yuji; Kubota, Keiichi; Saeki, Hidehisa; Gemma, Akihiko

doi:10.1186/s40425-019-0534-z

Cited by 9 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNF-α (tumor necrosis factor α) is a cytokine that stimulates inflammation ( Kroetsch et al, 2017 ). TNF α, a pro-inflammatory cytokine, can cause the ligamentum flavum to ossify ( Lin et al, 2018 ; Sugano et al, 2019 ). In humans, leptin (LEP) encodes the peptide hormone leptin (homolog of the mouse obesity gene) ( Min et al, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

Immune cell infiltration and the genes associated with ligamentum flavum hypertrophy: Identification and validation

Duan

Zhao

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Ligamentum flavum hypertrophy (LFH) is a common cause of spinal stenosis. The aim of the current study was to identify the differentially expressed genes (DEGs) in LFH and the molecular mechanisms underlying the development of and immune responses to LFH. The gene expression omnibus (GEO) database was used to obtain the GSE113212 dataset, and the DEGs were derived from microarray data. To identify critical genes and signaling pathways, gene ontology enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, and protein-protein interaction (PPI) network analyses were performed, followed by immune cell infiltration and Friends analyses using the retrieved datasets. The results were validated using quantitative real-time PCR. The 1530 DEGs identified comprised 971 upregulated and 559 downregulated genes. KEGG analysis revealed that DEGs were mostly enriched in the PI3K-Akt signaling pathway, while PPI network analysis identified tumor necrosis factor, interleukin (IL)-6, IL-10, epidermal growth factor receptor, and leptin as important nodes, which was validated by qPCR and IHC in human LFH tissues in vitro. A significant positive correlation was found between key LFH immune-related DEGs and several immune cell types, including T and B cells. The findings of the present study might lead to novel therapeutic targets and clinical approaches, as they provide insights into the molecular mechanisms of LFH.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune cell infiltration and the genes associated with ligamentum flavum hypertrophy: Identification and validation

Duan

Zhao

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…One example is the treatment of rheumatoid arthritis with infliximab, which lead to resolution of ILH. Another example is the treatment of lung adenocarcinoma with pembrolizumab leading to improvement of ILH [ 10 ]. One case that was associated with tonsillitis showed response to antibiotic therapy and tonsillectomy [ 11 ].…”

Section: Discussion/conclusionmentioning

confidence: 99%

Intralymphatic Histiocytosis: An Unusual Presentation

2021

View full text Add to dashboard Cite

Intralymphatic histiocytosis (ILH) is a rare cutaneous condition initially described in 1994 by O’Grady et al. It often appears as a red to violaceous, livedoid patch or plaque usually on the extremities. We present a 71-year-old female with a history of psoriasis, 50 pack years smoking and recent Legionnaires disease who came to us complaining of a red to violaceous, blanching, edematous, mildly tender lesion covering the left lower lip and extending to the chin and anterior neck. After multiple biopsies, ILH was confirmed and the patient was initially started on tacrolimus 0.1% ointment b.i.d., but there was no response. Then, she was started on oral pentoxifylline and intermittent topical steroids, as well as continuing the topical tacrolimus. There was again no response, so now she is taking a TNF-ɑ inhibitor as it appears to be a granulomatous process. These ILH cases are very rare and there is limited literature that describes one treatment as a cure. Treatment of ILH is very difficult, but several different therapies have been reported with varying success. If the disease is secondary to an underlying inflammatory disease or malignancy, then treatment of the primary disorder can lead to resolution of the ILH.

show abstract

“…The first PD-1 inhibitor pembrolizumab was approved by the FDA in 2014 for the treatment of melanoma and lung cancer whereas the first PD-L1 inhibitor, atezolizumab for the treatment of bladder cancer was approved in 2016 ( 57 , 58 ). Checkpoint inhibitors may have severe side effects in numerous organs (skin, gastrointestinal tract, endocrine tissues, and liver), and different tumor microenvironments have distinct mechanisms of immunosuppression ( 59 ).…”

Section: Classes Of Cancer Immunotherapymentioning

confidence: 99%

Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics

Zhou

Zou

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Tumor immunotherapy is an artificial stimulation of the immune system to enhance anti-cancer response. It has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing in recent years, and many treatments are in clinical and preclinical stages. Despite this progress, the special tumor heterogeneity and immunosuppressive microenvironment of solid tumors made immunotherapy in the majority of cancer cases difficult. Therefore, understanding how to improve the intratumoral enrichment degree and the response rate of various immunotherapy drugs is key to improve efficacy and control adverse reactions. With the development of materials science and nanotechnology, advanced biomaterials such as nanoparticle and drug delivery systems like T-cell delivery therapy can improve effectiveness of immunotherapy while reducing the toxic side effects on non-target cells, which offers innovative ideas for improving immunity therapeutic effectiveness. In this review, we discuss the mechanism of tumor cell immune escape and focus on current immunotherapy (such as cytokine immunotherapy, therapeutic monoclonal antibody immunotherapy, PD-1/PD-L1 therapy, CAR-T therapy, tumor vaccine, oncolytic virus, and other new types of immunity) and its challenges as well as the latest nanotechnology (such as bionic nanoparticles, self-assembled nanoparticles, deformable nanoparticles, photothermal effect nanoparticles, stimuli-responsive nanoparticles, and other types) applications in cancer immunotherapy.

show abstract

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

Cited by 9 publications

References 22 publications

Immune cell infiltration and the genes associated with ligamentum flavum hypertrophy: Identification and validation

Immune cell infiltration and the genes associated with ligamentum flavum hypertrophy: Identification and validation

Intralymphatic Histiocytosis: An Unusual Presentation

Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics

Contact Info

Product

Resources

About